Details for Patent: 12,629,337

Which drugs does patent 12,629,337 protect, and when does it expire?

Patent 12,629,337 protects DAPTOMYCIN and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 12,629,337

Title:	Daptomycin formulation
Abstract:	The present disclosure relates to a solid formulation of daptomycin comprising at least one branched aliphatic amino acid. Solid daptomycin formulation of the present disclosure shows improved reconstituted time. The disclosure further relates to a method of preparation of the solid daptomycin formulation according to this disclosure.
Inventor(s):	Barbara FUMIC
Assignee:	Hikma Pharmaceuticals USA Inc
Application Number:	US17/794,734
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 12,629,337

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Hikma	DAPTOMYCIN	daptomycin	POWDER;INTRAVENOUS	217415-001	Jan 30, 2023		RX	Yes	Yes	12,629,337		Y
Hikma	DAPTOMYCIN	daptomycin	POWDER;INTRAVENOUS	217415-002	Jan 30, 2023		RX	Yes	Yes	12,629,337		Y

International Family Members for US Patent 12,629,337

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2021227095
Brazil	112022015571
Canada	3168727
China	115038431